$271 Million is the total value of TANG CAPITAL MANAGEMENT LLC's 8 reported holdings in Q3 2015. The portfolio turnover from Q2 2015 to Q3 2015 was 33.3% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
HRTX | HERON THERAPEUTICS INC | $126,657,000 | -21.7% | 5,190,837 | 0.0% | 46.70% | -4.8% | |
LJPC | Buy | LA JOLLA PHARMACEUTICAL CO | $81,007,000 | +24.0% | 2,914,970 | +9.4% | 29.87% | +50.7% |
OPK | New | OPKO HEALTH INC | $20,815,000 | – | 2,475,000 | +100.0% | 7.68% | – |
BMRN | BIOMARIN PHARMACEUTICAL INC | $19,200,000 | -23.0% | 182,300 | 0.0% | 7.08% | -6.4% | |
OPKO HEALTH INCdebt 3.0% 2/1/33 | $18,247,000 | -44.9% | 14,000,000 | 0.0% | 6.73% | -33.1% | ||
MERRIMACK PHARMACEUTICALS INCnote 4.5% 7/15/20 | $5,259,000 | -28.2% | 3,500,000 | 0.0% | 1.94% | -12.8% | ||
BRLI | Exit | BIO-REFERENCE LABS INC | $0 | – | -900,000 | -100.0% | -11.26% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-11-16
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
HERON THERAPEUTICS INC | 37 | Q3 2023 | 55.0% |
LA JOLLA PHARMACEUTICAL CO | 34 | Q2 2022 | 37.1% |
ROCKET PHARMACEUTICALS INC | 20 | Q3 2023 | 31.6% |
BIOMARIN PHARMACEUTICAL INC | 18 | Q3 2017 | 12.1% |
ODONATE THERAPEUTICS INC | 17 | Q4 2021 | 69.8% |
ANAPTYSBIO INC | 16 | Q3 2023 | 18.4% |
COHERUS BIOSCIENCES INC | 15 | Q3 2023 | 2.7% |
EQUILLIUM INC | 13 | Q3 2023 | 1.2% |
RELMADA THERAPEUTICS INC | 12 | Q4 2022 | 6.2% |
MIRATI THERAPEUTICS INC | 11 | Q3 2023 | 10.9% |
View TANG CAPITAL MANAGEMENT LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
4 | 2024-02-14 |
4 | 2024-02-02 |
4 | 2023-12-18 |
13F-HR | 2023-11-14 |
4 | 2023-10-13 |
13F-HR | 2023-08-14 |
3 | 2023-06-01 |
4 | 2023-06-01 |
4 | 2023-05-30 |
View TANG CAPITAL MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.